Entering text into the input field will update the search result below

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul. 12, 2022 8:59 AM ETDyne Therapeutics, Inc. (DYN)By: Dulan Lokuwithana, SA News Editor

Motor neuron connecting to muscle fiber, 3D illustration

Dr_Microbe/iStock via Getty Images

  • Dyne Therapeutics (NASDAQ:DYN), a clinical-stage biotech focused on muscular diseases, said on Tuesday that health authorities in New Zealand cleared a clinical trial application to start a Phase 1/2 for DYNE-101, an experimental therapy for myotonic

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About DYN

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Dyne Therapeutics, Inc.
Replimune Group, Inc.
Novavax, Inc.
Prime Medicine, Inc.
Arcturus Therapeutics Holdings Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.